Research Events

22 Feb 2019

Organizers: IRB Barcelona
Date: Friday 22 February, 12.00h
Place: Felix Serratosa Hall, Parc Científic de Barcelona, Spain

Host: Dr. Manuel Serrano (IRB Barcelona)   

Abstract:

26 Feb 2019

Organizers: IRB Barcelona
Date: Tuesday 26 February, 10.00h
Place: Felix Serratosa Hall, Parc Científic de Barcelona, Spain

Host: Dr. Manuel Serrano (IRB Barcelona)   

 

Aging and Metabolism Program Extraordinary Seminar

28 Feb 2019

Gianmarco Di Mauro – Chromatin Structure and Function Laboratory
Title: “Functional analysis of the extraproteasomal ubiquitin receptor Dsk2/UBQLN in Drosophila and human cells”
Date and Time: Thursday, 28th February 2019. 11.00 h.
Room: Classroom number 61.102-61.104, first floor of the Doctor Aiguader building (Dr. Aiguader 80, Barcelona). - UPF Campus-Mar.
 

 

1 Mar 2019

Organizers: IRB Barcelona
Date: Friday 1st March, 12.00h
Place: Auditorium, Parc Cientific de Barcelona

 

Plenary Seminar

8 Mar 2019

Organizers: IRB Barcelona

Date: Friday, 8 March, 12:00h

Place: Felix Serratosa room

Host: Dr. Manuel Serrano, PhD - IRB Barcelona

 

Abstract

11 Mar 2019 - 12 Mar 2019

Organizer: IRB Barcelona & Fundació Esteve

Date: Monday and Tuesday, March 11-12, 09:00-18:00h
Place: Room Felix Serratosa, Parc Científic de Barcelona, Spain

 

8 Apr 2019 - 10 Apr 2019

Cancer is a multi-hit process involving mutations in oncogenes and tumour suppressors. It is altered by its environment including interactions between the tumour cells and the surrounding normal tissue, immune response, and whole body metabolism. As such, cancer studies benefit from whole animal platforms. The fruit fly Drosophila is an excellent, genetically-tractable system for modelling the development of cancer due to the conservation of cell signalling, proliferation, and survival networks between fly and human.

18 Nov 2019 - 20 Nov 2019

Stimulation of the immune system by blocking immunosuppressive checkpoints has shown spectacular impact in cancer therapy. There is increasing evidence that immunotherapy might elicit similar outcomes in non-oncological settings. This is the case, for example, of neurodegenerative disorders where blockade of immune checkpoints has beneficial effects.  More generally, aging is associated with a progressive unbalance in the composition and activity of the different components of the immune system.